DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced positive interim results from Part 1a of its Phase 2 study of DM199 for the treatment of preeclampsia. The study, which is open-label and investigator-sponsored, demonstrated statistically significant reductions in both systolic and diastolic blood pressure, as well as a significant reduction in the uterine artery pulsatility index. Importantly, DM199 did not cross the placental barrier and was generally safe and well-tolerated. The study achieved pre-specified safety and efficacy endpoints, reinforcing DM199's therapeutic potential as a first-in-class, disease modifying therapy for preeclampsia. Currently, there are no approved pharmacological treatments for preeclampsia in the United States and Europe. DiaMedica Therapeutics plans to discuss these interim results further during a conference call and webcast scheduled for July 17, 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。